AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03791242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cpap and ketogenic diet
Description: Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
Study NCT04714242 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab Injection
Description: Three monthly intravitreal injections of Ranibizumab
Study NCT03317470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic needs survey
Description: -11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
Study NCT03317470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic needs survey
Description: -11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
Study NCT03317470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Navigator
Description: * The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~* The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
Study NCT03317470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up survey
Description: -5 questions about the acceptability of the basic needs survey
Study NCT03317470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up survey
Description: -5 questions about the acceptability of the basic needs survey
Study NCT03317470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up survey (phase II participants only)
Description: -7 questions about the effectiveness of the life navigator
Study NCT01687075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CR8 a drug eluting coronary stent
Description: a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
Study NCT00714675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: 1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
Study NCT00714675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: 1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
Study NCT03715842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tub shaped design
Description: The tub-shaped inlay preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
Study NCT03715842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inlay shaped design
Description: The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
Study NCT01258244 — intervention group
Intervention type: OTHER
Intervention: Audiovisual Feedback
Description: EMTs will get audiovisual feedback on CPR technique during CPR
Study NCT00649883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Trivalent Inactivated vaccines Novartis
Description: Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
Study NCT00649883 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Trivalent Inactivated vaccines
Description: Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
Study NCT01182402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliance monitoring with electronic device
Description: Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
Study NCT04419610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRV027
Description: peptide for infusion
Study NCT04419610 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0.9%
Description: placebo comparator for infusion
Study NCT03638154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GF+GMSCs carried on β TCP
Description: surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).~Ibuprofen
Study NCT03638154 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: β TCP bone substitute only
Description: surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen
Study NCT02878538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone
Description: Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
Study NCT02878538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo phase
Description: Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
Study NCT00692484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
Study NCT00692484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine
Description: Povidone iodine scrub and paint. Administer topically.
Study NCT03584828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele Cardiac Rehabilitation
Description: A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program.
Study NCT01490450 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-945429
Description: Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Study NCT01490450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Study NCT01490450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Study NCT01490450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Study NCT03366688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBI306
Description: Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
Study NCT03366688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
Study NCT04363528 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Doppler Echo
Description: 2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart
Study NCT01704040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3157 (healthy participants)
Description: CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
Study NCT01704040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (healthy participants)
Description: Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
Study NCT01704040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3157 (asthmatic patients)
Description: CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
Study NCT01704040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (asthmatic patients)
Description: Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
Study NCT01704040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-16
Description: Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
Study NCT01704040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HRV-16
Description: Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
Study NCT02712476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mannitol
Description: This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
Study NCT02712476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
Study NCT02712476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: This drug is can be used alone or with mannitol for brain relaxation
Study NCT02712476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: mannitol alone is compared with placebo
Study NCT03614754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory evoked potentials
Description: Stimulation of the pudendal nerve while recording at the sensory cortex.
Study NCT00188344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic myotomy with partial fundoplication
Description: The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
Study NCT01709084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
Study NCT01709084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
Study NCT01709084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
Study NCT01987687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise at 55% of maximum power output for 30 min.
Study NCT01987687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: Rest for 30 min
Study NCT01987687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delay
Description: Delay between exercise and OGTT
Study NCT01636973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaporizing humidifier
Description: Vaporizing humidifier applying during one-lung ventilation
Study NCT04327765 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.5mg AZ-010
Description: Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
Study NCT04327765 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1mg AZ-010
Description: Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo
Study NCT04327765 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3mg AZ-010
Description: Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
Study NCT00069927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-XR®
Description: Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
Study NCT00069927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concerta®
Description: Concerta® 18 mg/day for 3-12 weeks depending on subject's response
Study NCT02013947 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2 weeks of exercise in low and moderate altitude
Description: Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).
Study NCT01414699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Variety
Description: These conditions will have snack served with an increase of fruit variety.
Study NCT01414699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Variety
Description: These conditions will receive a snack without a variety of fruit.
Study NCT04154670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be given intravenously
Study NCT02227628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acai polyphenolics
Description: Acai beverage was obtained from the Sambazon (San Clemente, CA).
Study NCT02227628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugary Beverage
Description: An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD\&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
Study NCT03789942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral surgery
Description: Oral surgery procedures
Study NCT03210389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
Study NCT04452045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SweetDreams
Description: SweetDreams is a mHealth adaptation of existing evidence-based sleep interventions. It is a user friendly and developmentally appropriate modularized 4-week web-based intervention available on computer, tablet or mobile phones.
Study NCT00625989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aeroallergen
Study NCT00625989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aeroallergen
Study NCT00054704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole
Study NCT00054704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03039400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided home exercise with web-based support
Description: Those in the web-based physio group will access their exercise program online and will be able to leave messages for their physiotherapist on the platform. Physiotherapists will monitor usage and respond to messages every two weeks.
Study NCT03039400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapist-guided home exercise with standard support
Description: Those in the standard care group will receive a written, home-based exercise program. Participants in the usual care group will be asked to keep an exercise diary, in paper format.
Study NCT00124059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel
Description: 400mg/day quetiapine
Study NCT00124059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg/day placebo
Study NCT00792194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day.
Study NCT03527134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
Study NCT01979159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Description: Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
Study NCT01645189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hunterase
Description: once weekly, 0.5mg/kg IV infusion
Study NCT00906802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R-Y reconstruction
Description: The reconstruction was performed by R-Y anastomosis.
Study NCT04272671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The intervention has the following components: 1) alerts given to providers to identify patients taking opioids or benzodiazepines (BZD) and therefore at risk for falls; 2) educational materials to inform providers on best practices for de-prescribing opioids and BZDs in patients at risk; and 3) recommendations on de-prescribing provided by a consultant pharmacist. Impact of the intervention will be evaluated using pre-post surveys evaluating changes in providers' knowledge, confidence, and skills as well as information from the EHR to evaluate impact of the intervention on de-prescribing opioids and BZDs.